Tag: CBT > DEA Rescheduling: Page 6

Federal Cannabis Legalization

Cannabis Rescheduling: Where Do We Go From Here?

The legal team at Vicente addressed the significance of the potential move to reschedule cannabis, detailing the ramifications for state-legal cannabis businesses and what could happen next, during a webinar. Here are 12 key takeaways from the event.

May 10, 2024

Cannabis Rescheduling

Cannabis Rescheduling FAQ: What Now?

From potential timelines to 280E to SAFER Banking, legal experts explain the implications of the federal government reclassifying cannabis as a less dangerous substance.

May 6, 2024

Cannabis Rescheduling

Former Deputy Attorney General James Cole Weighs in on Cannabis Rescheduling and What’s Next

Cole spoke on a media call organized by industry groups and said Congress must ‘act to create a unified regulatory environment that involves both the states and the federal government.’

May 1, 2024

Cannabis Rescheduling

Cannabis Rescheduling Reactions Mixed: While Some Applaud Potential, Others Push For More

Executives, lawmakers and nonprofit leaders weigh in on the significance and shortcomings of the DEA's move to reclassify cannabis as a less dangerous substance.

May 1, 2024

Cannabis Rescheduling

UPDATE: DEA Moves to Reschedule Cannabis

The federal agency that has long enforced prohibition aligns with the recommendation from the U.S. Department of Health and Human Services, FDA to reclassify cannabis as a Schedule III substance under the Controlled Substances Act.

April 30, 2024

Cannabis Rescheduling

Cannabis Rescheduling Update: Is a ‘Notoriously Secretive Agency’ Now Involved?

A report that HHS requested an opinion from the Department of Justices’ Office of Legal Counsel raises new questions and concerns. Attorney Shane Pennington explains why that request and the outcome would be crucial to the schedule review process and the industry’s future.

April 29, 2024

Cannabis Rescheduling

21 US Lawmakers Express Frustration With DEA’s Inaction on Cannabis Rescheduling

The 11 senators and 10 House representatives urged for swift action to remove cannabis from a Schedule I listing in a new letter.

April 25, 2024

California

The State of Federal Cannabis Reform Leads CBT’s Most-Read Articles in April

4/20 deals and events, California tax defaults, and nationwide municipal opt outs also highlighted Cannabis Business Times’ most popular stories this month.

April 25, 2024

Legislation and Regulation

Federal Cannabis Legalization and Reform: Where Are We in 2024?

U.S. cannabis reform hasn’t come easy amid a divided Congress, but plenty of opportunities remain on the table for the remainder of the year.

April 20, 2024

Florida

The Future of Hemp-Derived Delta-9 THC Headlines CBT’s Most-Read Articles for March

Readers also dove headfirst into Amazon’s delta-8 problems and a potential rescheduling roadblock with the DEA’s five-factor test this month.

March 28, 2024

Cannabis Rescheduling

3 GOP Senators Tell DEA Not to Reschedule Cannabis

Led by former presidential candidate Mitt Romney, the senators argue rescheduling would violate an international treaty in letter to DEA administrator.

March 27, 2024

Cannabis Rescheduling

DEA’s 5-Factor Test Makes Rescheduling Cannabis Impossible

After HHS used its own two-part test to determine the plant’s ‘currently accepted medical use,’ rescheduling opponents urge DEA to keep its five-part test.

March 19, 2024